These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28321778)

  • 1. Effects of miR-21 downregulation and silibinin treatment in breast cancer cell lines.
    Jahanafrooz Z; Motamed N; Bakhshandeh B
    Cytotechnology; 2017 Aug; 69(4):667-680. PubMed ID: 28321778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Evaluation of Silibinin Effects on Cell Cycling and Apoptosis in Human Breast Cancer MCF-7 and T47D Cell Lines.
    Jahanafrooz Z; Motameh N; Bakhshandeh B
    Asian Pac J Cancer Prev; 2016; 17(5):2661-5. PubMed ID: 27268647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deregulation of miR-21 and miR-155 and their putative targets after silibinin treatment in T47D breast cancer cells.
    Zadeh MM; Ranji N; Motamed N
    Iran J Basic Med Sci; 2015 Dec; 18(12):1209-14. PubMed ID: 26877850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silibinin-Induced Apoptosis and Downregulation of MicroRNA-21 and MicroRNA-155 in MCF-7 Human Breast Cancer Cells.
    Zadeh MM; Motamed N; Ranji N; Majidi M; Falahi F
    J Breast Cancer; 2016 Mar; 19(1):45-52. PubMed ID: 27066095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Silibinin on the Expression of Mir-20b, Bcl2L11, and Erbb2 in Breast Cancer Cell Lines.
    Ranapour S; Motamed N
    Mol Biotechnol; 2023 Dec; 65(12):1979-1990. PubMed ID: 36905464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of silibinin-loaded nano-niosomal coated with trimethyl chitosan on miRNAs expression in 2D and 3D models of T47D breast cancer cell line.
    Yazdi Rouholamini SE; Moghassemi S; Maharat Z; Hakamivala A; Kashanian S; Omidfar K
    Artif Cells Nanomed Biotechnol; 2018 May; 46(3):524-535. PubMed ID: 28509572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-21 regulates the ACAT1 gene in MCF-7 cells.
    Chanyshev MD; Razumova YV; Ovchinnikov VY; Gulyaeva LF
    Life Sci; 2018 Sep; 209():173-178. PubMed ID: 30092298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines.
    Fragni M; Bonini SA; Bettinsoli P; Bodei S; Generali D; Bottini A; Spano PF; Memo M; Sigala S
    Naunyn Schmiedebergs Arch Pharmacol; 2016 May; 389(5):529-38. PubMed ID: 26905520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells.
    Agarwal C; Singh RP; Dhanalakshmi S; Tyagi AK; Tecklenburg M; Sclafani RA; Agarwal R
    Oncogene; 2003 Nov; 22(51):8271-82. PubMed ID: 14614451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic anti-cancer effects of silibinin-etoposide combination against human breast carcinoma MCF-7 and MDA-MB-231 cell lines.
    Koushki M; Khedri A; Aberomand M; Akbari Baghbani K; Mohammadzadeh G
    Iran J Basic Med Sci; 2021 Sep; 24(9):1211-1219. PubMed ID: 35083008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Therapy with Silibinin Improves the Efficacy of Paclitaxel and Cisplatin in MCF-7 Breast Cancer Cells.
    Chavoshi H; Vahedian V; Saghaei S; Pirouzpanah MB; Raeisi M; Samadi N
    Asian Pac J Cancer Prev; 2017 Aug; 18(8):2243-2247. PubMed ID: 28843263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silibinin enhances ultraviolet B-induced apoptosis in mcf-7 human breast cancer cells.
    Noh EM; Yi MS; Youn HJ; Lee BK; Lee YR; Han JH; Yu HN; Kim JS; Jung SH
    J Breast Cancer; 2011 Mar; 14(1):8-13. PubMed ID: 21847388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
    Tyagi AK; Agarwal C; Chan DC; Agarwal R
    Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silibinin to improve cancer therapeutic, as an apoptotic inducer, autophagy modulator, cell cycle inhibitor, and microRNAs regulator.
    Jahanafrooz Z; Motamed N; Rinner B; Mokhtarzadeh A; Baradaran B
    Life Sci; 2018 Nov; 213():236-247. PubMed ID: 30308184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silibinin inhibits proliferation, induces apoptosis and causes cell cycle arrest in human gastric cancer MGC803 cells via STAT3 pathway inhibition.
    Wang YX; Cai H; Jiang G; Zhou TB; Wu H
    Asian Pac J Cancer Prev; 2014; 15(16):6791-8. PubMed ID: 25169527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines.
    Zhu W; Shan X; Wang T; Shu Y; Liu P
    Int J Cancer; 2010 Dec; 127(11):2520-9. PubMed ID: 20162574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERα down-regulation plays a key role in silibinin-induced autophagy and apoptosis in human breast cancer MCF-7 cells.
    Zheng N; Zhang P; Huang H; Liu W; Hayashi T; Zang L; Zhang Y; Liu L; Xia M; Tashiro S; Onodera S; Ikejima T
    J Pharmacol Sci; 2015 Jul; 128(3):97-107. PubMed ID: 26117209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
    Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
    Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silibinin inhibits endometrial carcinoma via blocking pathways of STAT3 activation and SREBP1-mediated lipid accumulation.
    Shi Z; Zhou Q; Gao S; Li W; Li X; Liu Z; Jin P; Jiang J
    Life Sci; 2019 Jan; 217():70-80. PubMed ID: 30452972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of miR-106b in tumorigenic actions of both prolactin and estradiol.
    Chen KE; Bustamante K; Nguyen V; Walker AM
    Oncotarget; 2017 May; 8(22):36368-36382. PubMed ID: 28422740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.